drugset / Trial / NCT00558272
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-01
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 4 mg | — |
| Subject | saracatinib | Small molecule | 175 mg | Oral |